Entrepreneur Success Story

News Archive

Indee Labs Secures Funding to Develop Unique Gene Therapy Manufacturing Technology in Australia

Indee Labs Secures Funding to Develop Unique Gene Therapy Manufacturing Technology in Australia Read Full Press Release Indee Labs will receive grant funding of nearly $1M from the Australian Government’s $35 million BioMedTech Horizons program. The project will see Indee Labs make a new generation of medicine, known as gene therapy, accessible to the masses. The impact of gene therapies [...]Read more

GraphWear Technologies Raises a $4.2M Series A

GraphWear Technologies Raises a $4.2M Series A Read Full Press Release GraphWear makes a graphene-based sensor technology that can provide biological information from sweat. Initially ideated to provide performance athletes with advanced information, the latest use case in the works for GraphWear is aimed at a needle-free glucose test, expected to hit the market three to four years down the [...]Read more

Enable Biosciences, Stanford, and JDRF announce $700K Research Partnership to Develop Improved Screening and Early Diagnosis Tests for Type 1 Diabetes

Enable Biosciences, Stanford, and JDRF announce $700K Research Partnership to Develop Improved Screening and Early Diagnosis Tests for Type 1 Diabetes Enable Biosciences, a UC Berkeley and Stanford-StartX diagnostics company at MBC BioLabs, and Stanford’s Division of Pediatric Endocrinology and Diabetes announce a two-year initiative to support the development of a revolutionary new technology for earlier, easier and more accurate [...]Read more

Naked Biome Entering Clinical Trials to Target Propionibacterium Acnes

Naked Biome Entering Clinical Trials to Target Propionibacterium Acnes Naked Biome is developing a probiotic therapy for acne. Instead of killing P. acnes, the QB3@953 startup, would have patients flood their faces with live, healthy strains of bacterium, ensuring the good bacterial will outcompete the bad. Full Scientific American Article

Read more

Pionyr Immunotherapeutics Completes $62M Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment

Pionyr Immunotherapeutics Completes $62M Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment Max Krummel, PhD, Pionyr Co-Founder and Robert E. Smith Endowed Chair in Experimental Pathology, UCSF Pionyr Immunotherapeutics, a company at QB3@953, is developing antibody therapeutics that increase the body’s antitumor immunity by rebalancing the myeloid infiltrate in the tumor microenvironment, announced the closing of a […]

Read more

Asilomar Bio and Koch Biological Solutions Agree to Exclusive Commercial License of Leading Yield Enhancement Technology

Asilomar Bio and Koch Biological Solutions Agree to Exclusive Commercial License of Leading Yield Enhancement Technology QB3@953 startup, Asilomar has developed a small molecule to improve plant stress response. Koch Biological Solutions, LLC has secured exclusive global rights to commercialize and market products containing Asilomar Bio’s flagship yield enhancement technology for foliar, in-furrow, and other modes of application on a […]

Read more

Logicink announces first product to market: Logicink UV

  On October 19, at Breakout Lab’s Unboxing event, LogicInk, a pioneer in programmable materials, announced its first product to market: LogicInk UV, a wearable that resembles a temporary tattoo and monitors your UV exposure, signaling when it is time to take action to prevent skin damage. The company’s first product, LogicInk UV, targets people concerned about radiation from the sun that can […]

Read more

Siolta Therapeutics wins the Bugs, Drugs, & Beyond QuickFire Challenge

  Johnson & Johnson Innovation, JLABS and the Janssen Human Microbiome Institute (JHMI) launched the second Bugs, Drugs, & Beyond QuickFire Challenge. Taking place in both San Francisco and Cambridge, the Challenge awarded winners with a customized package of support from the JHMI and JLABS, including coaching and $75,000 in funding or entrance to the South San Francisco or Boston JLABS sites, […]

Read more

Indee Labs closed a $1.3M angel round

  Indee Labs closed a $1.3M angel round Indee Labs recently closed a $1.3M angel round and demonstrated functional modification of human primary T-cells with high efficiency (30 to 60%), cell viability (>85%) and recovery (>90%) without T-cell exhaustion or activation. The team also signed its first customer — a clinical-stage biotechnology company developing gene-modified B-cell therapies for rare disease […]

Read more

OneSkin closes $2M Financing to reverse aging skin

  OneSkin closes $2M Financing to reverse aging skin OneSkin Technologies is working on optimizing their technology of in vitro tissue aging and quantitative measurement of anti-aging molecule effects over the age of skin models. This platform will allow them to screen for molecules that molecules that truly rejuvenate skin or prevent aging.

Read more
Page 1 of 212

Upcoming Event

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter